Search Results
34 Results for 'Vitamin D'
PAGE 1 OF 2
Technology
Once-A-Week Administration Of 25-Hydroxy Vitamin D3 To Sustain Elevated Steady-State Pharmacokinetic Blood Concentration
An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and ...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame | P08138US02
Technology
2-methylene-(20s,25r)-19,26-dinor-vitamin D Analogs
This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This comp...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame, Grazia Chiellini, Pawel Grzywacz | P08090US
Technology
2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 And Uses Thereof
This invention relates to vitamin D compounds, and more particularly to 2-methylene-1 α,25-dihydroxy-18,19,21-trinorvitamin D3 (DJ-55) and to pharmaceutical formulations that include this compound. T...
Learn More
Learn More
Hector DeLuca, Rafal Barycki, Lori Plum, Margaret Clagett-Dame | P06327US
Technology
2-methylene-1alpha-hydroxy-18,19,21-trinorvitamin D3 Analogs And Uses Thereof
This invention relates to vitamin D compounds, and more particularly to 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 (SX-99) and to pharmaceutical formulations that include this compound. The inv...
Learn More
Learn More
Hector DeLuca, Rafal Barycki, Lori Plum, Margaret Clagett-Dame | P06328US
Technology
2-methylene-19-nor-(23s)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone And 2-methylene-19-nor-(2
The invention provides 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“GC-3”), 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“HLV”), and re...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Pawel Grzywacz, Grazia Chiellini | P05291US
Technology
19,26,27-trinor-1alpha,25-dihydroxyvitamin D3 Compounds
This invention relates to vitamin D compounds, and more particularly to 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds such as 2α-methyl-19,26,27-trinor-(20S)-1α,25-dihydroxyvitamin D3 (“P...
Learn More
Learn More
Hector DeLuca, Lori Plum, Pawel Grzywacz, Margaret Clagett-Dame | P05370US
Technology
17,20(z)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P06097US
Technology
17,20(e)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P06117US
Technology
2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol And Its Uses
This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibit...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Margaret Clagett-Dame | P05163US
Technology
2-methylene-19,26,27-trinor-(20s)-1alpha-hydroxyvitamin D3 And Its Uses
This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound e...
Learn More
Learn More
Hector DeLuca, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P05125US
Technology
2alpha-methyl And 2beta- Methyl Analogs Of 19,26,27-trinor-(20s)-1alpha-hydroxyvitamin D3 And Their
This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the...
Learn More
Learn More
Hector DeLuca, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P05127US
Technology
1-Alpha, 25-Dihydroxy-24,24-Difluoro-19-Nor-Vitamin D3 Analogs And Their Pharmaceutical Uses
Disclosed are 1α,25-dihydroxy-24,24-difluoro-2-methylene-19-nor-vitamin D analogs and their pharmaceutical uses. These new vitamin D analogs are 19-nor-vitamin D analogs having two fluorine atom subs...
Learn More
Learn More
Hector DeLuca, Lori Plum, Agnieszka Flores, Hazel Holden, James Thoden | P150305US02
Technology
Synthesis And Biological Activity Of 2-Methylene Analogs Of Calcitriol And Related Compounds
Disclosed are 2-methylene analogs of vitamin D3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1α-hydroxy-2-methylen...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Izabela Sibilska-Kaminski | P160027US02
Technology
1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D Compounds With A 1,1-dimethylpropyl Side C
This invention discloses 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain, and pharmaceutical uses therefor. These compounds exhibit pronounced a...
Learn More
Learn More
Hector DeLuca, Rafal Sicinski, Lori Plum, Agnieszka Glebocka, Margaret Clagett-Dame | P06381US
Technology
(20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol And Its Uses
This invention discloses (20S)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation o...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame | P07496US
Technology
(20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol And Its Uses
This invention discloses (20S)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation o...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame | P07497US
Technology
17,20(z)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P09210US
Technology
17,20(e)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P09211US
Technology
2-methylene-19,26,27-trinor-(20s)-1alpha-hydroxyvitamin D3 And Its Uses
This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound e...
Learn More
Learn More
Hector DeLuca, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P09212US
Technology
2alpha-methyl And 2beta- Methyl Analogs Of 19,26,27-trinor-(20s)-1alpha-hydroxyvitamin D3 And Their
This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the...
Learn More
Learn More
Hector DeLuca, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P09213US
Technology
2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol And Its Uses
This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Lori Plum, Bulli Padmaja Tadi, Margaret Clagett-Dame | P09214US
Technology
2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol And Its Uses
This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibit...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Margaret Clagett-Dame | P09215US
Technology
Diastereomers Of 2-Methylene-19-Nor-22-Methyl-1alpha,25-Dihydroxyvitamin D3
Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are use...
Learn More
Learn More
Hector DeLuca, Agnieszka Flores, Pawel Grzywacz, Margaret Clagett-Dame, Lori Plum, Hazel Holden, James Thoden | P100048US03
Technology
(20s)-2-Methylene-19-Nor-22-Dimethyl-1alpha,25-Dihydroxyvitamin D3 And (20r)-2-Methylene-19-Nor-22-Dimethyl-1alpha,25-Dihydroxyvitamin D3
Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are usef...
Learn More
Learn More
Hector DeLuca, Agnieszka Flores, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame | P100057US02
Technology
Procedure For Crystallization Of (22e)-(24r)-2-Methylene-22-Dehydro-1alpha,24,25-Trihydroxy-19-Nor-Vitamin D3
Disclosed are methods of purifying the compound (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 to obtain the compound in crystalline form. The methods typically include the ...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Agnieszka Flores, James Thoden, Hazel Holden | P180077US02